Table 2.
Patient demographics and baseline characteristics
| Variable | Total (n = 84) | Wild-type PIK3CA (n = 74) | Mutant PIK3CA (n = 10) | p-value |
|---|---|---|---|---|
| Age (yr) | .100 | |||
| Median ± SD | 68 ± 12.6 | 68 ± 12.8 | 70 ± 9.7 | |
| Sex | .307 | |||
| Male | 49 (58.3) | 45 (60.8) | 4 (40.0) | |
| Female | 35 (41.7) | 29 (39.2) | 6 (60.0) | |
| Smoking | .324 | |||
| Yes | 47 (56.0) | 43 (58.1) | 4 (40.0) | |
| No | 37 (44.0) | 31 (41.9) | 6 (60.0) | |
| Alcohol drinking | .182 | |||
| Yes | 44 (52.4) | 41 (55.4) | 3 (30.0) | |
| No | 40 (47.6) | 33 (44.6) | 7 (70.0) | |
| Tumor location | .380 | |||
| Oral cavity | 57 (67.9) | 51 (68.9) | 6 (60.0) | |
| Tongue | 14 (16.7) | 13 (17.6) | 1 (10.0) | |
| Gums | 13 (15.4) | 12 (16.2) | 1 (10.0) | |
| Buccal mucosa | 11 (13.1) | 10 (13.5) | 1 (10.0) | |
| Floor of mouth | 6 (7.1) | 5 (6.7) | 1 (10.0) | |
| Lip | 5 (6.0) | 3 (4.1) | 2 (20.0) | |
| Hard palate | 4 (4.8) | 4 (5.4) | 0 | |
| Retromolar area | 2 (2.4) | 2 (2.7) | 0 | |
| Oral cavity (unspecified) | 2 (2.4) | 2 (2.7) | 0 | |
| Oropharynx | 6 (7.1) | 6 (8.1) | 0 | |
| Base of tongue | 6 (7.1) | 6 (8.1) | 0 | |
| Hypopharynx | 21 (25.0) | 17 (23.0) | 4 (40.0) | |
| Pyriform sinus | 21 (25.0) | 17 (23.0) | 4 (40.0) | |
| Clinical stage | .628 | |||
| I | 16 (19.0) | 14 (18.9) | 2 (20.0) | |
| II | 17 (20.3) | 13 (17.6) | 4 (40.0) | |
| III | 19 (22.6) | 18 (24.3) | 1 (10.0) | |
| IVa | 29 (34.5) | 26 (35.1) | 3 (30.0) | |
| IVb | 1 (1.2) | 1 (1.4) | 0 | |
| IVc | 2 (2.4) | 2 (2.7) | 0 | |
| Treatment | .337 | |||
| Surgery | 23 (27.4) | 18 (24.3) | 5 (50.0) | |
| Surgery followed by RT | 42 (50.0) | 38 (51.4) | 4 (40.0) | |
| RT | 13 (15.5) | 12 (16.2) | 1 (10.0) | |
| Best supportive care | 6 (7.1) | 6 (8.1) | 0 |
Values are presented as number (%) unless otherwise indicated.
PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; SD, standard deviation; RT, radiotherapy.